NIW Approved for Senior Scientist Developing Immunogenic Correlate-Guided Vaccines
Client’s Testimonial:
“I am incredibly grateful to the North America Immigration Law Group for their exceptional guidance and support throughout my EB-2 NIW petition process. As a Senior Scientist working in the field of infectious diseases and vaccine development, it was critical for me to partner with a legal team that truly understood the value and impact of my research. NAILG meticulously crafted a compelling petition that clearly articulated the national importance of my work on immunogenic correlate-guided vaccines. Their strategic approach, attention to detail, and deep expertise in handling scientific cases were instrumental in securing my approval, without even a Request for Evidence. I highly recommend NAILG to any researcher or scientist pursuing an NIW petition. Their professionalism and dedication are truly unmatched.”
On May 24th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Scientist in the Field of Infectious Diseases (Approval Notice).
General Field: Infectious Diseases
Position at the Time of Case Filing: Senior Scientist
Country of Origin: India
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: May 24th, 2025
Processing Time: 11 months, 7 days
Case Summary:
A client entrusted the North America Immigration Law Group (NAILG) with the preparation and filing of her EB-2 NIW petition. Her field of research—infectious disease therapeutics and vaccine development—places her at the forefront of public health innovation. By showcasing her pioneering work on immunogenic correlate-guided vaccines and her proven record of impactful scientific contributions, we successfully secured her petition’s approval without a Request for Evidence (RFE).
Developing Next-Generation Vaccines for Infectious Disease Mitigation
Our client’s research focuses on designing immunogenic correlate-guided vaccines to mitigate the global and national burden of diseases such as tuberculosis, malaria, measles, and Hepatitis B. Her work supports the development of therapeutic and prophylactic solutions using advanced molecular tools and high-throughput technologies.
Her studies have significantly advanced the understanding of how host-pathogen interactions can be modulated to improve immunity. Through her position at a leading U.S. biotechnology company, she continues to direct discovery-stage vaccine development programs that improve public health preparedness and combat pandemic-level threats.
Her Scientific Work Has Earned Broad Recognition
-
- 13 peer-reviewed journal publications, including 4 first-authored articles
- 353 citations across microbiology and immunology literature
- 4 publications ranked in the top 10–20% most cited in the field of immunology for their publication years
- 33 completed peer reviews for top-tier scientific journals
Notable Scientific Contributions Include:
● Targeting Protein Kinase G (PknG) for Tuberculosis Treatment: She demonstrated the viability of PknG deletion and inhibition as a therapeutic strategy, reducing Mtb survival and relapse potential in mouse models. ● Host-Directed Therapy Using SIRT2 Inhibitors: Her research revealed how modulating host epigenetic responses through SIRT2 inhibition enhances immune activation and TB treatment efficacy. ● Characterization of Mtb Survival Proteins (FtsQ, AosR, PPE2): Her discoveries advanced our understanding of pathogen resistance mechanisms and led to the identification of novel vaccine targets.
Her work has not only been cited extensively by global researchers but has also influenced ongoing projects in host-pathogen biology, vaccine design, and epigenetic immunotherapy.NAILG's Strategic Approach: Establishing National Interest
Our legal strategy emphasized how her proposed endeavor aligns with areas designated as “critical and emerging technologies” by the U.S. government, such as genome engineering and viral delivery systems. We also highlighted how her published work not only contributes to scientific knowledge but also informs practical vaccine development efforts that support American health and biosafety goals.
Through expert references, robust evidence of her citation metrics, and detailed documentation of her past and ongoing success, we established that:
● Her work has substantial merit and national importance. ● She is well-positioned to continue advancing her research. ● Waiving the job offer requirement would benefit the United States.
The final approval, issued without an RFE, underscores the strength of both the client’s qualifications and the legal arguments advanced by NAILG.